Liraglutide

is prescribed to treat:

• Type 2 diabetes and weight management • Various related conditions in the diabetes category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Liraglutide (Victoza, Saxenda) is a GLP-1 receptor agonist used for type 2 diabetes and, at a higher dose, for obesity and weight management. It was among the first GLP-1 agonists in wide use and established the class, though its once-daily injection schedule has since been superseded for most patients by weekly agents.

Mechanism of Action

Liraglutide is a modified analogue of human GLP-1, an incretin hormone released from the intestine after eating. Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4; liraglutide is structurally altered to resist that degradation and to bind albumin, extending its half-life to around 13 hours and allowing once-daily dosing.

It acts on several tissues. In the pancreas it enhances glucose-dependent insulin secretion and suppresses inappropriate glucagon release — glucose-dependence being why GLP-1 agonists rarely cause hypoglycemia alone. In the stomach it slows gastric emptying, prolonging satiety and blunting post-meal glucose rises. In the hypothalamus it acts on appetite regulation, reducing hunger and food intake.

The appetite effect accounts for most of the weight loss, and patients often describe it as reduced preoccupation with food rather than simple fullness.

Liraglutide also demonstrated cardiovascular benefit in the LEADER trial, reducing major adverse cardiovascular events in type 2 diabetes with high cardiovascular risk — a finding that shifted the class from glucose-lowering agents to organ-protective ones.

Clinical Use

In type 2 diabetes, liraglutide is recommended irrespective of A1c in patients with established atherosclerotic cardiovascular disease, and it is typically added to metformin. At the higher dose it is used for weight management, with mean weight loss smaller than that achieved with semaglutide or tirzepatide.

The once-daily injection is its main practical disadvantage relative to weekly agents, and most patients starting a GLP-1 agonist now begin on a weekly drug. Liraglutide retains a role where a weekly agent is unavailable, not covered, or not tolerated, and its shorter half-life is occasionally an advantage — side effects resolve faster on stopping, and it is easier to discontinue before surgery.

Titration is deliberate and slow, because gastrointestinal side effects are dose-related and abrupt escalation is the main reason patients quit. Nausea, vomiting, constipation, and reflux are common early and usually attenuate. Smaller meals, avoiding high-fat foods, and pausing escalation rather than abandoning treatment resolve most cases. The GLP-1 side effects article covers management in detail, and our endocrine team supervises therapy.

Weight regain after discontinuation is the rule rather than the exception, because the drug treats a chronic condition rather than curing it. Framing it as long-term therapy from the outset avoids the disappointment that follows an implicit expectation of a finite course.

Monitoring and Follow-Up

A1c is checked every three months until stable in diabetes; weight and waist circumference track response in obesity. Because liraglutide can reduce insulin and sulfonylurea requirements, those agents often need dose reduction at initiation to avoid hypoglycemia — the main setting in which a GLP-1 agonist contributes to low blood sugar.

Kidney function warrants attention during episodes of significant vomiting or diarrhoea, since volume depletion can precipitate acute kidney injury, and the drug should be held during such illness. Pancreatitis has been reported; severe persistent abdominal pain radiating to the back requires evaluation and drug cessation. Gallbladder disease occurs more frequently, largely as a consequence of rapid weight loss.

Muscle mass loss accompanies rapid weight loss and deserves active attention — adequate protein intake and resistance training preserve lean mass and are worth prescribing alongside the drug rather than mentioning in passing. The visceral fat article explains why the distribution of loss matters as much as the amount.

Injection technique and site rotation matter as with any subcutaneous injection. The MedlinePlus liraglutide entry covers administration detail, and the American Diabetes Association publishes patient-level guidance on where these agents fit.

The two brand names cause genuine confusion, because they are the same molecule at different doses for different indications — one licensed for type 2 diabetes and one for weight management, with different maximum doses, different packaging, and often very different insurance coverage. Patients occasionally end up prescribed both, or are switched between them without realising the dose has changed. Checking which product and which dose a patient is actually taking, rather than recording the drug name alone, avoids a category of error that recurs across this whole class.

Switching within the class is also straightforward and common. A patient tolerating liraglutide but finding daily injections burdensome can generally move to a weekly agent, and the conversion is by dose equivalence rather than by starting again from the lowest step — though some re-titration is usual to limit gastrointestinal effects.

Special Populations

Liraglutide carries a boxed warning about thyroid C-cell tumours based on rodent studies whose human relevance is unestablished. It is contraindicated in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

It should be discontinued before a planned pregnancy and is not used during pregnancy or breastfeeding. Because it delays gastric emptying, current guidance is to inform the anaesthesia team before any procedure requiring sedation. In older adults it is effective, though weight loss in the frail elderly is not universally desirable and muscle preservation matters more. Severe gastroparesis is a relative contraindication, and significant kidney impairment warrants caution given dehydration risk.

When to Contact Your Doctor

Seek prompt care for severe, persistent abdominal pain, particularly radiating to the back and accompanied by vomiting, which may indicate pancreatitis. Report persistent vomiting or diarrhoea causing reduced fluid intake, since dehydration and kidney injury follow.

Right upper abdominal pain, fever, or jaundice may signal gallbladder disease. A neck lump, difficulty swallowing, or persistent hoarseness should be reported. Report symptoms of low blood sugar if you also take insulin or a sulfonylurea.

Tell any surgeon or anaesthetist that you take a GLP-1 agonist before a procedure, and hold the drug during any acute illness with reduced oral intake.

To discuss whether a GLP-1 agonist is right for you, manage side effects, or consider switching to a weekly agent, contact us or schedule a visit.